Fig. 4.

The non-tumorigenic FGF19 analogue M52 retains BA synthesis regulatory activity in Fxr^null mice but does not protect Fxr^null mice against DSS-induced colitis. (a) qRT-PCR of hepatic Cyp7a1, Cyp7b1 and Cyp8b1. Expression was normalized to Cyclophillin. (b) Plasma BA composition (CA/MCA Ratio). (c) Percentage of initial body weight during DSS treatment, (d) visible rectal bleeding score, (e) hemoccult score and (f) colon length in AAV-FGF19-M52- vs AAV-GFP-injected Fxr^null mice. Representative H&E-stained colonic sections for (g) AAV-GFP- and (h) AAV-FGF19-M52-injected FXR^null mice (Magnification 200X). (i) Histology and (j) goblet cell loss scores. (k) In vivo intestinal permeability measurement after DSS-induced intestinal inflammation in FXR^null mice. All values represent means±SEM. Statistical significance comparing AAV-FGF19-M52 versus control AAV-GFP assessed by Mann-Whitney's U test (*p < 0.05, **p < 0.01, ***p < 0.001).